Is Climb Bio Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Climb Bio Inc (CLYM) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Climb Bio Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Climb Bio Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Climb Bio Inc?

Muslim investors may consider investing in Climb Bio Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Climb Bio Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Climb Bio Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Climb Bio Inc updated?

The Shariah compliance status of Climb Bio Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Climb Bio Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Climb Bio Inc?

You can check the latest Shariah compliance status of Climb Bio Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CLYM Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 09, 2026

Report Source: 2025 Annual Report

Climb Bio Inc. Stock Analysis CLYM

United States Health Care Small Cap Report: 2025 Annual

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Key Statistics of Climb Bio Inc (CLYM)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$10.62$11.17

Today's Open

$11.04

Volume

655.31K

P/E Ratio (TTM)

52 Week Range

$1.13$12.48

Market Cap

546.95M

Avg. Volume

936.01K

Dividend Yield

Financial Metrics & Statements of Climb Bio Inc (CLYM)

FAQ's for Climb Bio Inc (CLYM)

According to Musaffa’s Shariah screening methodology, Climb Bio Inc (CLYM) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.